Jump to navigation Jump to search

Clinical data
  • US: X (Contraindicated)
Routes of
ATC code
Pharmacokinetic data
Protein binding97%
MetabolismHepatic, minor (CYP3A4-mediated)
Elimination half-life30 hours
ExcretionRenal and fecal
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass366.493 g/mol

WikiDoc Resources for Drospirenone


Most recent articles on Drospirenone

Most cited articles on Drospirenone

Review articles on Drospirenone

Articles on Drospirenone in N Eng J Med, Lancet, BMJ


Powerpoint slides on Drospirenone

Images of Drospirenone

Photos of Drospirenone

Podcasts & MP3s on Drospirenone

Videos on Drospirenone

Evidence Based Medicine

Cochrane Collaboration on Drospirenone

Bandolier on Drospirenone

TRIP on Drospirenone

Clinical Trials

Ongoing Trials on Drospirenone at Clinical Trials.gov

Trial results on Drospirenone

Clinical Trials on Drospirenone at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Drospirenone

NICE Guidance on Drospirenone


FDA on Drospirenone

CDC on Drospirenone


Books on Drospirenone


Drospirenone in the news

Be alerted to news on Drospirenone

News trends on Drospirenone


Blogs on Drospirenone


Definitions of Drospirenone

Patient Resources / Community

Patient resources on Drospirenone

Discussion groups on Drospirenone

Patient Handouts on Drospirenone

Directions to Hospitals Treating Drospirenone

Risk calculators and risk factors for Drospirenone

Healthcare Provider Resources

Symptoms of Drospirenone

Causes & Risk Factors for Drospirenone

Diagnostic studies for Drospirenone

Treatment of Drospirenone

Continuing Medical Education (CME)

CME Programs on Drospirenone


Drospirenone en Espanol

Drospirenone en Francais


Drospirenone in the Marketplace

Patents on Drospirenone

Experimental / Informatics

List of terms related to Drospirenone

Drospirenone is a synthetic progestin that is an analog to spironolactone. Its molecular weight is 366.5 and its molecular formula is C24H30O3.

Properties and uses

The compound is part of certain birth control formulations. Drospirenone differs from other synthetic progestins in that its pharmacological profile in preclinical studies shows it to be closer to the natural progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogen-stimulated activity of the renin-angiotensin-aldosterone system, and is not androgenic. With its activities similar to spironolactone it may lead to less water retention and breast tenderness and improved skin appearance (less acne).

Drospirenone is taken orally with about 76% bioavailability. It is not bound by sex hormone binding globulin or corticosteroid binding globulin, but by other serum proteins. Metabolites have not been shown to be biologically active, show up in urine and feces, and are essentially completely excreted within 10 days.

The compound is part of certain newer oral contraceptive formulations:

  • Yasmin® contains 3 mg drospirenone and 30 mcg ethinylestradiol per tablet. It is indicated for the prevention of pregnancy in women who elect an oral contraceptive.
  • Yaz® contains 3 mg drospirenone and 20 mcg ethinylestradiol per tablet and is given for 24/4 days with the same indications.

It has also been formulated in medication to manage menopausal symptoms using 0.5 mg drsp and 1 mg estradiol per day by oral application. This medication was introduced in the USA in 2007 as Angeliq®.

Drospirenone, which can potentially cause hyperkalemia in high-risk patients, is comparable to a 25mg dose of spironolactone.

The medication is contraindicated in patients with hepatic dysfunction, renal insufficiency, adrenal insufficiency, or in whom the use of oral contraceptives is contraindicated, such as smokers and patients with a history of DVT, stroke, or other blood clots. Because of the anti-mineralocorticoid effects care needs to be exercised when other drugs that may increase potassium levels are taken. Such medications include ACE inhibitors, angiotensin-II receptor agonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDs.

See also


  • Krattenmacher R (2000). "Drospirenone: pharmacology and pharmacokinetics of a unique progestogen". Contraception. 62 (1): 29–38. PMID 11024226.
  • Yasmin product information
  • Angeliq product information

External links

Template:Sex hormones de:Drospirenon nl:Drospirenon

Template:WikiDoc Sources